These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36305753)

  • 21. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
    Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
    Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.
    Babiker HM; Riaz IB; Husnain M; Borad MJ
    Oncolytic Virother; 2017; 6():11-18. PubMed ID: 28224120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of novel therapies for melanoma.
    Karimkhani C; Gonzalez R; Dellavalle RP
    Am J Clin Dermatol; 2014 Aug; 15(4):323-37. PubMed ID: 24928310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016.
    Brzozowska M; Wierzba W; Śliwczyński A; Świerkowski M; Potemski P; Marczak M
    Melanoma Res; 2018 Feb; 28(1):52-55. PubMed ID: 29120964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
    Ma C; Armstrong AW
    J Dermatolog Treat; 2014 Oct; 25(5):401-8. PubMed ID: 23763243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in targeted nanoparticles drug delivery to melanoma.
    Li J; Wang Y; Liang R; An X; Wang K; Shen G; Tu Y; Zhu J; Tao J
    Nanomedicine; 2015 Apr; 11(3):769-94. PubMed ID: 25555352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
    Schmitt AM; Dumas L; Larkin J
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
    Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
    Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
    J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
    [No Abstract]   [Full Text] [Related]  

  • 32. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R; Hoeller C; Gruter IP; Michielin O
    Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel targets in the treatment of advanced melanoma: new first-line treatment options.
    Culos KA; Cuellar S
    Ann Pharmacother; 2013 Apr; 47(4):519-26. PubMed ID: 23548648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
    Trojaniello C; Festino L; Vanella V; Ascierto PA
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous melanoma: new advances in treatment.
    Foletto MC; Haas SE
    An Bras Dermatol; 2014; 89(2):301-10. PubMed ID: 24770508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin.
    Zou L; Ding W; Zhang Y; Cheng S; Li F; Ruan R; Wei P; Qiu B
    Biomaterials; 2018 Nov; 182():1-12. PubMed ID: 30096444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis.
    Garzón-Orjuela N; Prieto-Pinto L; Lasalvia P; Herrera D; Castrillón J; González-Bravo D; Castañeda-Cardona C; Rosselli D
    Dermatol Ther; 2020 Mar; 33(2):e13145. PubMed ID: 31664762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotechnology for the treatment of melanoma skin cancer.
    Naves LB; Dhand C; Venugopal JR; Rajamani L; Ramakrishna S; Almeida L
    Prog Biomater; 2017 May; 6(1-2):13-26. PubMed ID: 28303522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.